Abstract
Transthyretin is a homotetrameric protein that carries thyroxine and retinol binding protein in plasma and is associated with a variety of amyloid diseases. One approach to the potential treatment of TTR amyloidosis is the stabilization of the native tetramer, over the dissociative transition state, through the binding of small molecules; this increases the kinetic barrier for tetramer dissociation and prevents protein misfolding. Several molecules discovered through focused screening, or created utilizing the structure-based design, were studied to identify the structural features that could make up for a good candidate drug. In this review, we examine several different chemical classes of TTR fibril formation inhibitors, highlighting the structural modifications that have led to an improvement or to a decrease of their potency and/or selectivity.
Keywords: Transthyretin (TTR), TTR-amyloidosis, familial transthyretin amyloidosis (FAP, FAC, SSA), protein-misfolding disorders, TTR amyloid fibril formation inhibitors, structure based drug discovery, amyloid fibril formation inhibitors, SAR
Current Medicinal Chemistry
Title:TTR Fibril Formation Inhibitors: Is there a SAR?
Volume: 19 Issue: 15
Author(s): S. Nencetti, E. Orlandini
Affiliation:
Keywords: Transthyretin (TTR), TTR-amyloidosis, familial transthyretin amyloidosis (FAP, FAC, SSA), protein-misfolding disorders, TTR amyloid fibril formation inhibitors, structure based drug discovery, amyloid fibril formation inhibitors, SAR
Abstract: Transthyretin is a homotetrameric protein that carries thyroxine and retinol binding protein in plasma and is associated with a variety of amyloid diseases. One approach to the potential treatment of TTR amyloidosis is the stabilization of the native tetramer, over the dissociative transition state, through the binding of small molecules; this increases the kinetic barrier for tetramer dissociation and prevents protein misfolding. Several molecules discovered through focused screening, or created utilizing the structure-based design, were studied to identify the structural features that could make up for a good candidate drug. In this review, we examine several different chemical classes of TTR fibril formation inhibitors, highlighting the structural modifications that have led to an improvement or to a decrease of their potency and/or selectivity.
Export Options
About this article
Cite this article as:
S. Nencetti, E. Orlandini , TTR Fibril Formation Inhibitors: Is there a SAR?, Current Medicinal Chemistry 2012; 19 (15) . https://dx.doi.org/10.2174/092986712800269326
DOI https://dx.doi.org/10.2174/092986712800269326 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Approaches for Administering Chemotherapy in the Intensive Care Unit
Current Drug Safety Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor
Current Topics in Medicinal Chemistry Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets Natriuretic Peptide Guided Heart Failure Management
Current Clinical Pharmacology Differentiation of Mesenchymal Stem Cells from Humans and Animals into Insulin-producing Cells: An Overview <i>In Vitro</i> Induction Forms
Current Stem Cell Research & Therapy The Interaction Between Gender and Diabetes Mellitus in the Coronary Heart Disease Risk
Current Pharmaceutical Design Postoperative Atrial Fibrillation - What Do We Really Know?
Current Vascular Pharmacology Polymorphism Gln27Glu of β2 Adrenergic Receptors in Patients with Ischaemic Cardiomyopathy
Current Vascular Pharmacology Targeting Mitochondria for Cardiac Protection
Current Drug Targets Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Cardiac Autonomic Nervous System in Heart Failure: Imaging Technique and Clinical Implications
Current Cardiology Reviews Selectivity Problems with Drugs Acting on Cardiac Na<sup>+</sup> and Ca<sup>2+</sup> Channels
Current Medicinal Chemistry Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design The Role of Oxidative Stress in Smoking-Related Diseases
Mini-Reviews in Organic Chemistry Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial
Current Gene Therapy Drug Uptake Systems in Liver and Kidney
Current Drug Metabolism Induction and Escalation Therapies in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry